Evolus, Inc., a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults; and Nuceiva, for the temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown. It also provides dermal filler products under the Estyme and Evolysse names. The company was incorporated in 2012 and is headquartered in Newport Beach, California.
Market Dynamics | Delve into the competitive landscape of medical aesthetics, where Evolus faces established players while leveraging educational initiatives to gain market share. |
Product Pipeline | Explore Evolus' growth strategy, centered on Jeuveau's performance and the potential launch of Evolysse Fillers, set to expand the company's market reach. |
Financial Trajectory | Discover Evolus' path to profitability, with Q4 2024 projections and analyst expectations of EPS improvement from -0.22 in FY1 to 0.04 in FY2. |
Aesthetic Innovato | Evolus Inc. positions itself as a key player in medical aesthetics, focusing on toxins and fillers, with ambitious revenue targets and a growing market presence. |
Metrics to compare | EOLS | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEOLSPeersSector | |
---|---|---|---|---|
P/E Ratio | −19.5x | −1.9x | −0.6x | |
PEG Ratio | −0.83 | 0.02 | 0.00 | |
Price / Book | 53.6x | 0.7x | 2.6x | |
Price / LTM Sales | 4.4x | 1.2x | 3.2x | |
Upside (Analyst Target) | 52.3% | 85.9% | 47.5% | |
Fair Value Upside | Unlock | 27.0% | 6.7% | Unlock |